CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety

Isabella Piassi Godói, Livia Lovato Pires Lemos, Vânia Eloisa de Araújo, Braúlio Cesar Bonoto, Brian Godman, Augusto Afonso Guerra Júnior

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

INTRODUCTION: Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia(®)) was the first vaccine to gain regulatory approval to try and address this problem.  AIM: Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine.  METHOD: Meta-analysis and systematic review.  RESULTS: The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2-16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events.  CONCLUSION: CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.

LanguageEnglish
Number of pages16
JournalJournal of Comparative Effectiveness Research
Early online date13 Jan 2017
DOIs
Publication statusE-pub ahead of print - 13 Jan 2017

Fingerprint

Dengue Vaccines
Meta-Analysis
Vaccines
Safety
Dengue Virus
Erythema
Vaccination
Population
CYD-TDV vaccine

Keywords

  • dengue
  • meta-analysis
  • systematic review
  • vaccines

Cite this

Godói, Isabella Piassi ; Pires Lemos, Livia Lovato ; de Araújo, Vânia Eloisa ; Bonoto, Braúlio Cesar ; Godman, Brian ; Guerra Júnior, Augusto Afonso. / CYD-TDV dengue vaccine : systematic review and meta-analysis of efficacy, immunogenicity and safety. In: Journal of Comparative Effectiveness Research. 2017.
@article{fc1ef869060f4c02b9b8e047335f80f5,
title = "CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety",
abstract = "INTRODUCTION: Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia({\circledR})) was the first vaccine to gain regulatory approval to try and address this problem.  AIM: Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine.  METHOD: Meta-analysis and systematic review.  RESULTS: The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60{\%} was derived from studies with participants aged 2-16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events.  CONCLUSION: CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.",
keywords = "dengue, meta-analysis, systematic review, vaccines",
author = "God{\'o}i, {Isabella Piassi} and {Pires Lemos}, {Livia Lovato} and {de Ara{\'u}jo}, {V{\^a}nia Eloisa} and Bonoto, {Bra{\'u}lio Cesar} and Brian Godman and {Guerra J{\'u}nior}, {Augusto Afonso}",
year = "2017",
month = "1",
day = "13",
doi = "10.2217/cer-2016-0045",
language = "English",
journal = "Journal of Comparative Effectiveness Research",
issn = "2042-6313",

}

CYD-TDV dengue vaccine : systematic review and meta-analysis of efficacy, immunogenicity and safety. / Godói, Isabella Piassi; Pires Lemos, Livia Lovato; de Araújo, Vânia Eloisa; Bonoto, Braúlio Cesar; Godman, Brian; Guerra Júnior, Augusto Afonso.

In: Journal of Comparative Effectiveness Research, 13.01.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CYD-TDV dengue vaccine

T2 - Journal of Comparative Effectiveness Research

AU - Godói, Isabella Piassi

AU - Pires Lemos, Livia Lovato

AU - de Araújo, Vânia Eloisa

AU - Bonoto, Braúlio Cesar

AU - Godman, Brian

AU - Guerra Júnior, Augusto Afonso

PY - 2017/1/13

Y1 - 2017/1/13

N2 - INTRODUCTION: Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia(®)) was the first vaccine to gain regulatory approval to try and address this problem.  AIM: Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine.  METHOD: Meta-analysis and systematic review.  RESULTS: The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2-16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events.  CONCLUSION: CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.

AB - INTRODUCTION: Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia(®)) was the first vaccine to gain regulatory approval to try and address this problem.  AIM: Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine.  METHOD: Meta-analysis and systematic review.  RESULTS: The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2-16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events.  CONCLUSION: CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.

KW - dengue

KW - meta-analysis

KW - systematic review

KW - vaccines

UR - http://www.futuremedicine.com/doi/10.2217/cer-2016-0045

U2 - 10.2217/cer-2016-0045

DO - 10.2217/cer-2016-0045

M3 - Article

JO - Journal of Comparative Effectiveness Research

JF - Journal of Comparative Effectiveness Research

SN - 2042-6313

ER -